Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.31 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.31 |
| ▸ | RARA | P10276 | 1/20 | 0.31 |
| ▸ | RARB | P10826 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12624499 | 0.85 | — | — | |
| SCHEMBL12622617 | 0.84 | OPRL1 (0.34) | CYP2C9DGAT1 | |
| SCHEMBL12624344 | 0.84 | — | — | |
| SCHEMBL12622624 | 0.83 | OPRL1 (0.33) | MAPTDGAT1P2RY14 | |
| SCHEMBL12622618 | 0.83 | OPRL1 (0.33) | MAPTDGAT1P2RY14 | |
| SCHEMBL16560261 | 0.82 | CYP2C9 (0.34) | CYP2C9NR1H4ALDH1A1LMNAMAPT | |
| SCHEMBL12622616 | 0.81 | OPRL1 (0.34) | CYP2C9DGAT1 | |
| SCHEMBL12622760 | 0.81 | CYP2C9 (0.34) | CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL12622868 | 0.81 | CYP2C9 (0.34) | CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL12622385 | 0.80 | PDE2A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951432-B2 | Five-ring liquid crystal compound having cyclohexane ring, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20090302273-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND HAVING CYCLOHEXANE RING, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090302273-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND HAVING CYCLOHEXANE RING, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | ZYX, PYM1, CPNE4 | CYP2C9 813/4885NR1H4 1630/4885ALDH1A1 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.